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Summary Over the past years immuno-oncology has
evolved and become a novel promising strategy for
cancer therapy. Immune checkpoint inhibitors such
as pembrolizumab or nivolumab, which target the
interaction between programmed death receptor 1/
programmed death ligand 1 (PD-1/PDL-1) and PDL-
2, have been recently approved for the treatment of
various malignancies and are currently being inves-
tigated in clinical phase III trials for head and neck
squamous cell carcinoma (HNSCC). Data available
from these trials indicate substantial activity accom-
panied by a favorable safety and toxicity profile in this
patient population. This review article focuses on the
molecular background, gives an overview of current
clinical data of checkpoint inhibitors in HNSCC, and
points out future challenges such as the need for
appropriate biomarkers for these novel compounds.
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Introduction
Beginning from the late 19th century, when William
Cloey treated cancer with a mixture of killed bac-
teria, until the modern era of checkpoint inhibitors
immunotherapy has evolved to a powerful weapon
for anticancer treatment. The relevance of an intact
host immune response for cancer prevention has been
initially demonstrated in animal experiments, which
showed an increased incidence of tumors in mice with
deficiencies in the innate or adaptive immune system
[1, 2]. Consistently, persons with HIV/AIDS have a 2–6
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fold increased risk for the development of oropharyn-
geal cancer compared to the general population [3].
It is generally accepted that immunosurveillance, i. e.,
the recognition and elimination of malignant cells by
the immune system constantly occurs in humans as
well. Based on the concept of immunosurveillance
the term immunoediting was coined. Immunoediting
is a dynamic process consisting of tumor elimination,
equilibrium, and tumor escape (Fig. 1; [4]). Tumor
elimination represents the successful eradication of
the evolving tumor by the immune system. However,
if the tumor is not completely destroyed, tumor cells
might enter an equilibrium state, where the immune
system controls tumor outgrowth but elimination re-
mains incomplete [2, 5]. The equilibrium might last
for years but negatively selects tumor cells, which can
evade the immune system.
Relevance of immune cell infiltration in head and
neck cancer
Head and neck squamous cell carcinoma (HNSCC)
induces an immune suppressive state via various
mechanisms. Patients with HNSCC have altered
lymphocyte homeostasis (mainly reduced levels of
CD3+, CD4+, and CD8+ T cells) compared to healthy
controls [6]. This imbalance even remains 2 years
after treatment with curative intent [6]. Consistently,
a higher number of tumor infiltrating CD4+ and CD8+
lymphocytes is associated with better overall survival
in HNSCC patients [7]. Additionally, natural killer
cell (NK) function is impaired in HNSCC patients,
which is accompanied by elevated levels of TGF beta
and soluble major histocompatibility complex Class I
chain-related peptide A [8, 9]. In human papilloma
virus (HPV)-positive oropharyngeal carcinoma pa-
tients, an increased number of CD56+ cytotoxic NK
cells was reported, which might contribute to the fa-
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Fig. 1 Theprinciple of immunoediting consistingof tumor
elimination, anequilibriumphase, and tumor escape
vorable prognosis of this subpopulation [10]. The role
of regulatory FoxP3+ T-cells (T regs) is still a matter of
debate in HNSCC. A recent meta-analysis suggested
that T regs are even favorable with respect to prog-
nosis in HNSCC [11]. While the anti-inflammatory
effect of T regs might contribute to this finding, only
a subpopulation of T regs such as CD4+, CD25 high+,
and FoxP3+, which were described to be elevated in
HNSCC, are activated and act as potent immunosup-
pressors [12]. Finally, myeloid depressor cells (MDSC)
and macrophages of the M2 phenotype are found in
HNSCC tissues and peripheral blood facilitating an
immunosuppressive state [5].
Immune escape mechanisms in head and neck
cancer
HNSCC cells apply certain strategies to escape im-
munosurveillance and subsequent elimination. On
the one hand they interact indirectly with the immune
system in order to maintain an immunosuppressive
microenvironment. Secretion of cytokines such as
TGF beta, interleukin 10, or VEGF establishes a tumor-
promoting immunosuppressive environment [2]. Ad-
ditional factors such as the secretion of interleukin 6,
which prevents the activation of T cells, NK cells or
dendritic cells maturation via STAT3, further modu-
lates the cellular immune system resulting in condi-
tions, which facilitate immune escape [2].
On the other hand a key component for immune
escape of HNSCC cells is the reduction of their in-
herent immunogenicity by downregulating (but not
complete loss) human leukocyte antigen (HLA) class I
molecules and disrupting of the antigen-processing
machinery (APM) [13]. Apart from that HNSCC exploit
the fact that the immune system is tightly regulated
through immune checkpoints in order to avoid au-
toimmunity or immune system over-activation under
physiological circumstances.
Immune checkpoints
In recent years the introduction of immune check-
point inhibitors for therapeutic purposes has revo-
Fig. 2 PDL-1/PD-1 interaction for T-cell activitymodulation
lutionized cancer treatment. T cell regulation, i. e.,
activation or inhibition is mediated via co-stimula-
tory or co-inhibitory signals. This interaction is ex-
erted via ligand/receptor interaction. T cells harbor
a myriad of both activating receptors such as OX-40,
GITR, or CD 28 and inhibitory receptors (the so-called
immune checkpoints) such as programmed death re-
ceptor 1 (PD-1) or cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) [14]. Activation of this immune
checkpoints results in T cell deactivation (Fig. 2; [15]).
Hijacking these pathways by tumor cells contributes
to their successful immune escape. For HNSCC tu-
mors it has been reported that 45–80% express pro-
grammed death ligand 1 (PDL-1) [16]. In addition,
exposure of HNSCC cells to therapy can result in tu-
mor PDL-1 upregulation: It has been observed that
HNSCC patients have elevated PDL-1 expression com-
pared to healthy controls and that chemotherapy and
radiation causes an PDL-1 upregulation in HNSCC pa-
tients, which lasts up to one year [17]. PDL-1 over-
expression in tumor cells is induced via extrinsic in-
terferon gamma secretion by NK or CD8+ cells or by
intrinsic oncogenic drivers [18]. Very recently, the
EGFR/JAK2/STAT-1 axis was identified for HNSCC to
act as such a driver pathway [18]. Apart from that,
HNSCC cells can respond to cetuximab treatment with
recruitment of CD4+, FOXP3+ intra-tumoral T regs ex-
pressing CTLA-4, CD39, and TGFβ, which results in
suppression of cetuximab-mediated antibody-depen-
dent cellular cytotoxicity (ADCC) and poor prognosis
[19]. Preclinical data indicate that CTLA-4 blockade
with the monoclonal antibody ipilimumab might re-
store cetuximab sensitivity [20].
Clinical immunotherapy data
Currently there are dozens of clinical trials evaluating
the efficacy and safety of immune checkpoint in-
hibitors as monotherapy or in combination regimens
in HNSCC. Table 1 lists selected clinical trials with
PD-1, PD-L1, and CTLA-4 inhibitors, which are
tested in HNSCC at the moment. Data that the
PD-1 antibody pembrolizumab might be effective
in metastatic/recurrent (R/M) HNSCC patients were
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Table 1 Selectedclinical immunotherapy trials inHNSCCpatients
Clinical trial title Phase Target Population
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or
Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
III PD-1 R/M HNSCC after platinum failure
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent
or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475 048/
KEYNOTE-048)
III PD-1 R/M HNSCC first line
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT
in Patients With Locally Advanced HNSCC (PembroRad)
II PD-1 plus Radia-
tion
Locally advanced HNSCC
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic
Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232)
I PD-1 plus on-
colytic virus
R/M HNSCC after platinum failure
Trial of Nivolumab vs Therapy of Investigator’s Choice in Recurrent or
Metastatic Head and Neck Carcinoma (CheckMate 141)
III PD-1 R/M HNSCC after platinum failure
Study of Nivolumab in Combination With Ipilimumab Compared to the Stan-
dard of Care (Extreme Study Regimen) as First Line Treatment in Patients
With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and
Neck (CheckMate 651)
II PD-1/CTLA-4 R/M HNSCC first line
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of
Solid Tumors
I PD-1/LAG-3 R/M HNSCC immunotherapy naive
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab
Versus Standard of Care Therapy in Patients With Head and Neck Cancer
III PDL-1/CTLA-4 R/M HNSCC after platinum failure
generated in the Keynote 12 phase I/II trial. This study
had a head and neck cohort (inclusive expansion) and
included 132 patients with R/M HNSCC, who were
partially heavily pretreated (37% had 3 or more lines
of therapy). Patients received pembrolizumab 200 mg
every 3 weeks. Primary objective was objective re-
sponse rate (ORR), which was reported to be 24.8%.
Of note both HPV+ and HPV- patients responded
to therapy [21]. Pembrolizumab therapy was very
well tolerated. The majority of patients (59.8%) had
grade 1/2 adverse events (AE) with fatigue being the
most predominant one. Severe immune-related AEs
such as pneumonitis was reported in 5 patients (3.8%)
[21].
Very recently the data of the randomized check-
mate 141 phase III trial were presented [22]. This
study investigated the efficacy of the monoclonal
PD-1 antibody nivolumab given every 2 weeks in
platinum-refractory R/M HNSCC patients compared
to investigator’s choice (cetuximab, methotrexate, or
docetaxel). Primary objective was overall survival
(OS). The study was stopped early due to superiority
of the nivolumab arm. Patients receiving nivolumab
had a median OS of 7.5 months and a 1-year OS rate
of 36% compared to 5.1 months and 16.6% in the
standard arm (HR 0.70; CI: 0.51–0.96; p = 0.0101) [22].
In the subgroup analysis it was shown that the sur-
vival benefit was more prominent in the p16+ group
and especially patients with a PDL-1 expression >1%
benefited from the treatment. Of note the study was
not designed to find OS differences with respect to
p16 or PDL-1 status and was positive for the overall
study population [22]. In terms of toxicity no new
safety issues arose compared to the Keynote 012 trial.
Apart from checkpoint inhibitors several other im-
munotherapy strategies, which are not focus of this
review article, such as adoptive cell transfer or can-
cer vaccines are in clinical development. Oncolytic
viruses selectively target cancer cells, deliver antigens,
and cause a host immune response. The attenu-
ated herpes simplex virus talimogene laherparepvec
(T-VEC) has been recently approved for melanoma
treatment and studies in HNSCC (in combination
with checkpoint inhibitors) are underway [23].
Biomarkers for checkpoint inhibitor therapy
Identification of predictive biomarkers in order to se-
lect patients, who benefit from checkpoint inhibitor
treatment will be crucial. The first and obvious poten-
tial biomarker is the evaluation of PDL-1 expression
in tumor tissue. However, several shortcomings are
linked to this approach. First, there a technical is-
sues, as there are several, partially not validated,
PDL-1 antibodies available for immunohistochem-
istry and no cut-off level has been defined for posi-
tivity so far. Second, PDL-1 is a dynamic biomarker,
which expression might vary even within the tu-
mor tissue or depending on the time point. Fi-
nally, the observation that also patients, who do not
show PDL-1 expression, might respond to check-
point blockade is well documented [24]. In non-
small cell lung cancer it has been shown that pa-
tients, who are heavy smokers, respond better to
nivolumab compared to never smokers [25]. This
phenomenon can be explained with a higher mu-
tational burden in this patient population, which
results in neo-antigen release and a subsequent boost
in immunogenicity of the tumor. Since HNSCC cells
were found to harbor one of the highest somatic
mutation frequency among all solid tumors and sim-
ilar molecular smoking patterns were identified in
HNSCC patients, this concept might apply to HNSCC
as well [26]. In addition, the role of PDL-2, another
ligand of the PD-1 receptor is still poorly understood.
Data from the keynote 12 trial showed that there is
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a discordance between PDL-1 and PDL-2 expression
in a subpopulation of patients and suggest that PDL-
2 expression is associated with higher ORR after ad-
justing for PDL-1 expression [27]. However, further
research is necessary to incorporate these findings
into the daily clinical practice.
Conclusion and perspectives
No new drugs have been approved for HNSCC since
the introduction of cetuximab more than 10 years ago.
Phase III trial results of the checkpoint inhibitor tri-
als are eagerly awaited and the approval of nivolumab
based on the checkmate 141 data can be expected in
2016/2017. Trials evaluating combinations of check-
point inhibitors with other costimulatory or inhibitory
molecules or oncolytic viruses are ongoing. Finally,
there is sound scientific rationale to incorporate im-
munotherapy in curative treatment protocols for non
R/M HNSCC and to go for an immunotherapy com-
bination with radio(chemo)therapy. All in all, im-
munotherapy offers exciting new perspectives for pa-
tients suffering from HNSCC after years of negative
clinical trials.
Conflict of interest T. Fuereder declares that there are no
competing interests.
Open Access. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. MaparaMY,SykesM.Toleranceandcancer:mechanismsof
tumor evasionand strategies for breaking tolerance. JClin
Oncol. 2004;22:1136–51. doi:10.1200/jco.2004.10.041.
2. Muenst S, et al. The immune system and cancer evasion
strategies: therapeutic concepts. J Intern Med. 2016;
doi:10.1111/joim.12470.
3. Gillison ML. Oropharyngeal cancer: a potential conse-






5. Ferris RL. Immunology and immunotherapy of head
and neck cancer. J Clin Oncol. 2015;33:3293–304.
doi:10.1200/jco.2015.61.1509.
6. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL.
Decreased absolute counts of T lymphocyte subsets and
their relation to disease in squamous cell carcinoma of
the head and neck. Clin Cancer Res. 2004;10:3755–62.
doi:10.1158/1078–0432.ccr-04-0054.
7. Nguyen N, et al. Tumor infiltrating lymphocytes and
survival in patients with head and neck squamous cell
carcinoma.HeadNeck. 2016;doi:10.1002/hed.24406.
8. Dasgupta S, Bhattacharya-Chatterjee M, O’Malley BW.
InhibitionofNK cell activity throughTGF-beta 1 by down-
regulation of NKG2D in amurinemodel of head and neck
cancer. J Immunol. 2005;175:5541–50.
9. Kloss S, et al. Increased sMICA and TGFbeta levels in
HNSCC patients impair NKG2D-dependent functionality




significance in oropharyngeal squamous cell carcinoma.
IntJCancer. 2016;138:2263–73. doi:10.1002/ijc.29962.
11. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of
tumor-infiltrating FoxP3+ regulatory T cells in cancers: a
systematicreviewandmeta-analysis. SciRep. 2015;5:15179
doi:10.1038/srep15179.
12. Badoual C, et al. Prognostic value of tumor-infiltrating
CD4+T-cell subpopulations inheadandneckcancers. Clin
Cancer Res. 2006;12:465–72. doi:10.1158/1078-0432.ccr-
05-1886.
13. LalamiY,AwadaA.Innovativeperspectivesofimmunother-
apy in head and neck cancer. From relevant scientific
rationale to effective clinical practice. Cancer Treat Rev.
2016;43:113–23. doi:10.1016/j.ctrv.2016.01.001.
14. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy




16. Zandberg DP, Strome SE. The role of the PD-
L1:PD-1 pathway in squamous cell carcinoma of
the head and neck. Oral Oncol. 2014;50:627–32.
doi:10.1016/j.oraloncology.2014.04.003.
17. Parikh F, et al. Chemoradiotherapy-induced upregulation
of PD-1 antagonizes immunity toHPV-relatedoropharyn-
gealcancer. CancerRes. 2014;doi:10.1158/0008-5472.can-
14-1913.
18. Concha-Benavente F, et al. Identification of the cell-
intrinsicand-extrinsicpathwaysdownstreamofEGFRand
IFNgammathat inducePD-L1expression inheadandneck
cancer. Cancer Res. 2016;76:1031–43. doi:10.1158/0008-
5472.can-15-2001.
19. Agrawal N, et al. Exome sequencing of head and neck
squamous cell carcinoma reveals inactivating mutations
in NOTCH1. Science. 2011;333:1154–7. doi:10.1126/
science.1206923.
20. Jie HB, et al. CTLA-4(+) regulatory T cells increased in
cetuximab-treatedheadandneckcancerpatientssuppress





23. Kohlhapp FJ, Kaufman HL. Molecular pathways: mech-
anism of action for talimogene laherparepvec, a new
oncolytic virus immunotherapy. Clin Cancer Res.
2016;22:1048–54. doi:10.1158/1078-0432.ccr-15-2667.
24. Brahmer J, et al. Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
2015;373:123–35. doi:10.1056/NEJMoa1504627.
25. BorghaeiH, etal. Nivolumabversusdocetaxel inadvanced
nonsquamous non-small-cell lung cancer. N Engl J Med.
2015;373:1627–39. doi:10.1056/NEJMoa1507643.
26. Alexandrov LB, et al. Signatures of mutational processes
in human cancer. Nature. 2013;500:415–21. doi:10.1038/
nature12477.
27. Yearly. ECCO2015,oralpresentation.
K Immunotherapy for head and neck squamous cell carcinoma 69
